Identification of metabolites of Yiqi Baoyuan Prescription in rat plasma, bile, urine and feces after oral administration.
10.19540/j.cnki.cjcmm.20220215.204
- Author:
Yi-Ying ZHANG
1
;
Li-Ping WU
2
;
Yi-Fan FENG
2
;
Hui REN
2
;
Hong-Jie KANG
3
;
Yue ZHU
1
;
Sheng GUO
1
;
Shu-Lan SU
1
;
Da-Wei QIAN
1
;
Jin-Ao DUAN
4
Author Information
1. Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine Nanjing 210023, China.
2. Jiangsu Key Laboratory for Traditional Chinese Medicine Formulae Research, Nanjing University of Chinese Medicine Nanjing 210023, China.
3. Ningxia Goji Innovation Center Yinchuan 750002, China.
4. National-Local Joint Engineering Research Center of Resource Industrialization of Chinese Materia Medica and Prescriptionoriented Innovative Drugs, Nanjing University of Chinese Medicine Nanjing 210023, China.
- Publication Type:Journal Article
- Keywords:
Yiqi Baoyuan Prescription;
mass defect filter(MDF);
metabolites;
ultra-high performance liquid chromatography coupled to time-of-flight mass spectrometry(UPLC-TOF-MS)
- MeSH:
Administration, Oral;
Animals;
Bile/chemistry*;
Chromatography, High Pressure Liquid/methods*;
Feces/chemistry*;
Prescriptions;
Rats;
Rats, Sprague-Dawley
- From:
China Journal of Chinese Materia Medica
2022;47(16):4469-4479
- CountryChina
- Language:Chinese
-
Abstract:
This study was designed to determine the metabolites of Yiqi Baoyuan Prescription(YQBYP) in rats. The ultra-high performance liquid chromatography coupled to time-of-flight mass spectrometry(UPLC-TOF-MS) and mass defect filter(MDF) were employed to analyze the metabolites of YQBYP in rat plasma, bile, urine and feces. Chromatographic separation was conducted on Acquity UPLC BEH C_(18) column(2.1 mm×100 mm, 1.7 μm) under gradient elution with 0.1% formic acid aqueous solution(A)-acetonitrile(B), and the column temperature was 30 ℃. Electrospray ion(ESI) source was used under positive and negative ion modes, with capillary voltage of 3.0 kV and mass scanning range of m/z 100-1 000. In this experiment, 9 prototype components and 36 metabolites were identified in rat plasma, bile, urine and feces samples. The results showed that the main metabolic pathways of YQBYP in rats involved methylation, demethylation, oxidation, and other phase Ⅰ reactions as well as glucuronidation, sulfation, and other phase Ⅱ reactions. This study provided scientific basis for clarifying the therapeutic material basis of YQBYP and product development.
